Topics in Anti-Cancer Research : Volume 7.

Cover -- Title -- Biblography -- End User License Agreement -- Contents -- Preface -- Introduction -- List of Contributors -- The Role of ncRNAs in Human Cancer and its Related Patents -- María I. Navarro-Mendoza1, Carlos Pérez-Arques1, Laura Murcia1, Alfonso F. López-Martínez2 and Francisco E. Nicolás1,* -- 1. INTRODUCTION -- 2. SMALL NCRNAS: MIRNAS, PIRNAS, TIRNAS, SNORNAS AND PARNAS -- 2.1. miRNAs -- 2.2. piRNAs -- 2.3. tiRNAs -- 2.4. snoRNAs -- 2.5. Small Promoter Associated RNAs -- 2.6. Other Small ncRNAs -- 3. LONG NCRNAS: LINCRNAS, T-UCRS, CERNAS AND OTHER LNCRNAS -- 3.1. LincRNAs -- 3.2. T-UCRs -- 3.3. CeRNAs -- 3.4. Other lncRNAs -- CURRENT &amp -- FUTURE DEVELOPMENTS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- DISCLOSURE -- REFERENCES -- Taxol To Nanotaxol: A Journey Towards Enhanced Drug Delivery -- Tanvi Kaku1, Aiswarya Dash2 and Biswa P. Chatterji2,* -- 1. INTRODUCTION -- 1.1. Methods for Preparation of Paclitaxel Nanoparticles -- 1.1.1. CN1463969A -- 1.1.2. CN101829061A -- 1.2. Human Serum Albumin (HSA) Associated and Other Protein Associated and Functionalized Taxol® or Paclitaxel Nanoparticles as Drug Delivery Agents -- 1.2.1. US6506405B1 -- 1.2.2. US8268348B2 and US20100112077A1 -- 1.2.3. WO1994018954A1 -- 1.2.4. US20040092577A1 -- 1.2.5. US20090004118 -- 1.2.6. US20090226393 -- 1.2.7. US20100015051 -- 1.2.8. US20100303723 -- 1.2.9. WO2007034479 -- 1.3. Micelles, Emulsions and Liposomes as Drug Delivery Carriers for Paclitaxel -- 1.3.1. US20150366806 -- 1.3.2. WO2009070761 -- 1.3.3. EP2494956 and EP2494957 -- 1.3.4. WO1994007484 -- 1.3.5. WO1996002247 -- 1.3.6. CN102772368A -- 1.3.7. US5424073 -- 1.3.8. KR101612194 -- 1.3.9. US8663599B1 -- 1.4. Carbon Nanoparticles as Drug Delivery Agents for Cancer Chemotherapy -- 1.4.1. EP3063091 -- 1.4.2. US20090087493 -- 1.4.3. KR20180016231 -- 1.4.4. CN104998261.

1.4.5. WO2014015334 -- 1.5. Nanodevices for Paclitaxel Delivery to Cancer Cells -- 1.5.1. US20100215724 -- 1.5.2. US20100303716 -- DISCUSSION -- CURRENT &amp -- FUTURE DEVELOPMENTS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Advanced Therapy in Cancer: Stimuli-Responsive Nanocarriers for On-Demand Drug Delivery -- Azadeh Haeri*, Fatemeh Mehryab and Hamid R. Moghimi -- 1. INTRODUCTION -- 2. STIMULI-RESPONSIVE NANOCARRIERS -- 3. EXTERNAL STIMULI-RESPONSIVE DRUG DELIVERY -- 3.1. Temperature-Responsive Nanocarriers -- 3.2. Magnetic Field-Responsive Nanocarriers -- 3.3. Photo-Responsive Nanocarriers -- 3.4. Ultrasound-Responsive Nanocarriers -- 4. INTERNAL STIMULI-RESPONSIVE DRUG DELIVERY -- 4.1. pH-Responsive Nanocarriers -- 4.2. Enzyme-Responsive Nanocarriers -- 4.3. Redox-Responsive Nanocarriers -- 5. OTHER STIMULI-RESPONSIVE NANOCARRIERS -- CONCLUSION -- CURRENT &amp -- FUTURE DEVELOPMENTS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Regulation and the Function of Autophagy in the Development and Behavior of Esophageal Cancers -- Erdem Ayik* and Gulsum O. Elpek -- 1. INTRODUCTION -- 2. GENERAL ASPECTS OF AUTOPHAGY -- 3. AUTOPHAGY IN CANCER -- 3.1. AP in Malignant Transformation -- 3.2. AP in Cancer Behavior and Treatment -- 4. AUTOPHAGY IN ESOPHAGEAL CANCER -- 4.1. Autophagy in the Development of EAC -- 4.2. Autophagy in the Development of ESCC -- 4.3. Autophagy in EAC Behavior and Treatment -- 4.3.1. AP-Related Findings on Tumor Behavior and Progression in Patients with EAC -- 4.3.2. In Vitro Investigation of AP in EAC -- 4.4. Autophagy in ESCC Behavior and Treatment -- 4.4.1. AP-Related Findings in Tumor Behavior and Progression in Patients with ESCC -- 4.4.2. In Vitro Investigation of AP in ESCC -- CONCLUSION -- CURRENT &amp -- FUTURE DEVELOPMENTS.

CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- LIST OF ABBREVIATIONS -- REFERENCES -- Recent Patents on Smart Nano-Formulations for Cancer Therapy -- Shaheen Sultana*, Mohammad Yusuf and Maria Khan -- 1. INTRODUCTION -- 1.1. Polymer-Based Nano-Formulations -- 1.1.1. Polymeric Nanoparticles -- 1.1.2. Hydrogels -- 1.1.3. Dendrimers -- 1.1.4. Micelles -- 1.2. Virus-Based Nanoparticles -- 1.3. Carbon Nanotubes -- 1.4. Lipid-Based Nano-Formulation -- 1.4.1. Liposomes -- 1.4.2. Solid Lipid Nanoparticles -- 1.5. Metal-Based Nanoparticles -- 1.5.1. Gold Nanoparticles (AuNPs) -- 1.5.2. Magnetic Nanoparticles (MNPs) -- CONCLUSION -- CURRENT &amp -- FUTURE DEVELOPMENTS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Potential Inflammatory Mechanisms Underlying Chemotherapy-Induced Peripheral Neuropathy and Skeletal Muscle Effects -- Claire E. Feather1,2,4, John B. Kwok4,5, Gila Moalem-Taylor3,4 and Patsie Polly1,2,4,* -- 1. INTRODUCTION -- 1.1. Chemotherapy, Neuropathic Pain and Skeletal Muscle Effects -- 1.2. Clinical Insights -- 2. AN OVERVIEW OF CHEMOTHERAPY-INDUCED NEUROMUSCULAR EFFECTS -- 2.1. Chemotherapy-Induced Peripheral Neuropathy (CIPN) -- 2.1.1. Animal Models -- 2.2. Effects of Chemotherapy on Muscle -- 2.2.1. Animal Models -- 3. CHEMOTHERAPY AND INFLAMMATION -- 3.1. Cytokines -- 3.2. Reactive Oxygen Species -- 4. INFLAMMATION-ASSOCIATED MOLECULAR PATHWAYS OF INTEREST -- 4.1. Upstream Inflammatory Signaling Pathways -- 4.2. Endoplasmic Reticulum Stress -- 4.3. Paclitaxel-Specific Molecular Alterations -- 5. GENETIC SUSCEPTIBILITY TO CHEMOTHERAPY-INDUCED NEUROMUSCULAR EFFECTS -- 6. CANCER-INDUCED AND CHEMOTHERAPY-INDUCED EFFECTS -- 7. RECENT DEVELOPMENTS IN THE TARGETING OF CHEMOTHERAPY-INDUCED NEUROMUSCULAR EFFECTS -- CONCLUSION -- CURRENT &amp -- FUTURE DEVELOPMENTS.

CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Recent Advances in Nutrigenomics: Patent Applications -- Elvan Y. Akyuza, Ozlem Aytekina, Banu Bayrama and Yusuf Tutara,b,* -- 1. INTRODUCTION -- 1.1. Nutrigenomics and its Relation to Cancer -- 1.2. Nutrition, Epigenetics, and Genome Stability -- 1.3. Diet and Cancer Prevention -- 1.4. Composition and Method to Optimize and Customize Nutritional Supplement Formulations by Measuring Genetic and Metabolomic Contributing Factors to Disease Diagnosis, Stratification, Prognosis, Metabolism, and Therapeutic Outcomes - US20060062859 -- 1.5. Nutraceutical Compositions and Methods with Biologically Active Ingredients -US20080317734 -- 1.6. Diagnostic System for Selecting Nutrition and Pharmacological Products for Animals - US7873482 -- 1.7. System and Method for Evaluating and Providing Nutrigenomic Data, Information and Advice - US7877273 -- 1.8. Multi-Stage Nutrigenomic Diagnostic Food Sensitivity Testing in Animals - US8450072 -- 1.9. Predictive Markers for Cancer and Metabolic Syndrome - US2013045535 -- 1.10. Novel Compositions from Nigella Sativa - US20150004266 -- 1.11. Method of Dietary Treatment for Genetic and Epigenetic Diseases and Disorders - US20170056357 -- 1.12. Bioenergetics Profiling of Circulating Blood Cells and Systems, Devices, and Methods Relating Thereto - US2015024795 -- CONCLUSION -- CURRENT &amp -- FUTURE DEVELOPMENTS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Author Index -- Subject Index -- Back Cover.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.